The liquid biopsy era is finally here.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Encouraging immune responses and a competitive safety profile in a small trial seem to make Novavax’s vaccine a contender.
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Suddenly 2020’s medtech M&A landscape looks very different.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.